NCT05177653 (GA-19) is a NA clinical trial of Intravenous infusion in Pancreatectomy; Hyperglycemia, sponsored by University Hospital, Gentofte, Copenhagen.

Who is sponsoring NCT05177653?

NCT05177653 is sponsored by University Hospital, Gentofte, Copenhagen.

What drugs are being tested in NCT05177653?

Interventions in NCT05177653: Intravenous infusion, Intravenous infusion, Intravenous infusion, Intravenous infusion.

What condition does NCT05177653 study?

NCT05177653 studies Pancreatectomy; Hyperglycemia.

Is NCT05177653 still recruiting?

NCT05177653 is currently completed. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT05177653: GA-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Separate and Combined Extrapancreatic Effects of the Incretin Hormones

Completed NA Last updated 29 March 2023

What this trial tests

NA trial testing Intravenous infusion in Pancreatectomy; Hyperglycemia in 13 participants. Completed in 3 March 2023.

Timeline

7 April 2022

Primary endpoint
3 March 2023

3 March 2023

Quick facts

Lead sponsor	University Hospital, Gentofte, Copenhagen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	13
Start date	7 April 2022
Primary completion	3 March 2023
Estimated completion	3 March 2023
Sites	1 location across Denmark

Drugs / interventions tested

Intravenous infusion — full drug profile →
Intravenous infusion — full drug profile →
Intravenous infusion — full drug profile →
Intravenous infusion — full drug profile →

Conditions studied

Pancreatectomy; Hyperglycemia — all drugs for Pancreatectomy; Hyperglycemia →

Sponsor

University Hospital, Gentofte, Copenhagen

Who can join

Adults 30 to 70, any sex, with Pancreatectomy; Hyperglycemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) is secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas. The hormones also exert effects outside the pancreas, but especially for GIP, these are poorly investigated. Because of this, only GLP-1 based drugs (GLP-1 receptor agonists) are on the market for the treatment of type 2 diabetes and obesity. Nonetheless, a new drug is in clinical development: a combined GIP-GLP-1-receptor agonist (tirzepatide), which has shown better results than GLP-1 alone. The mechanism behind these impressive effects are unknown and in this study, the investigators will look into the exptrapancreatic effects of GIP and GLP-1, separate and combined and thus elucidate the mechanisms of action of this new drug class.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Intravenous infusion

Trials testing the same drug.

NCT03378414 — Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia · Phase 2 · not yet recruiting

Other recruiting trials for Pancreatectomy; Hyperglycemia

Currently open trials in the same condition.

NCT03260387 — A Prospective Observational Study of TPIAT · active not recruiting

Other University Hospital, Gentofte, Copenhagen trials

Trials by the same sponsor.

NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05177653 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05177653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing